Triple drug therapy for new type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial is testing a combination of three diabetes medicines (henagliflozin, retagliptin, and metformin) in people newly diagnosed with type 2 diabetes. The goal is to see if this triple therapy works better for controlling blood sugar compared to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been recently diagnosed with type 2 diabetes and are not yet on medication.
- You are 18 years or older.
- Your HbA1c (a 3-month blood sugar average) is between 8% and 11%.
- Your body mass index (BMI) is between 19 and 35.
- Your kidney function (eGFR) is 60 or higher.
- You are willing to sign a consent form and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different diabetes medicines to see which works best for people with type 2 diabetes who also have heart or blood vessel risks. It aims to find better treatment to protect your heart and kidneys.
This trial tests a combination of three diabetes medicines to see if they can quickly get high blood sugar under control in people newly diagnosed with type 2 diabetes. It's designed for those whose HbA1c is 9.0% or higher.
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
This study tests a new medicine (HM11260C) to see if it helps people with type 2 diabetes who are already taking metformin and dapagliflozin but still have high blood sugar. If you qualify, it could give you a new option to better control your diabetes.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
This trial tests a new medicine called HDM1005 for people with type 2 diabetes who haven't been helped enough by diet and exercise alone, and who haven't taken any diabetes medication in the last 12 weeks. It aims to see if the medicine can help lower blood sugar levels safely.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.